{
  "abstract": "Background and Importance Obesity and type 2 diabetes are common in advanced chronic kidney disease (CKD), increasing cardiovascular risk and limiting access to kidney transplantation. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves glycaemic control, promotes weight reduction, and reduces cardiovascular risk in the general population. However, evidence in haemodialysis patients is scarce, emphasising the need for real-world data.Aim and Objectives To describe changes in renal and cardiovascular parameters in obese stage V CKD patients undergoing haemodialysis treated with semaglutide, and to characterise their clinical profile and concomitant therapies.Material and Methods A retrospective case series was conducted between January 2022 and March 2025. Nine haemodialysis patients receiving subcutaneous semaglutide were included. Data extracted from electronic medical records included demographics, comorbidities, concomitant treatments, and duration of therapy. Renal parameters were serum creatinine, urea, and glomerular filtration rate (GFR, CKD-EPI). Cardiovascular parameters included HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP) and cardiovascular events. Statistical analysis was performed using RStudio v2024.12.1.Results Nine patients (55% female, median age 71 years (interquartile range (IQR): 61-75)) were included; 89% had type 2 diabetes and all had stage V CKD. Median treatment duration was 325 days (range 33–1047). Concomitant treatments included lipid-lowering agents (89%), antihypertensives (78%), insulin (67%), and oral antidiabetics (56%). Frequent comorbidities were dyslipidaemia (89%), hypertension (78%), heart failure (44%), atrial fibrillation (22%), and ischaemic heart disease (22%).Renal outcomes: creatinine decreased from 8.07 to 6.87 mg/dL (–14.9%, p=0.07), urea from 134.9 to 101.4 mg/dL (–23.8%, p=0.003), GFR showed no significant change (6.89→7.33 mL/min, p=0.426).Cardiovascular outcomes: HbA1c decreased from 6.89% to 6.22% (–9.7%, p=0.066), SBP from 140.7 to 125.8 mmHg (–14.9 mmHg, p<0.001), DBP remained unchanged. One cardiovascular event occurred after 51 days of treatment.Conclusion and Relevance Treatment with semaglutide in obese patients on haemodialysis was associated with slight stabilisation of renal function, a significant reduction in serum urea, and improved blood pressure, as well as moderate glycaemic improvement. These findings suggest potential cardio-renal benefits in a population often excluded from clinical trials. Larger prospective studies are warranted.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "I Marín Espinosa"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "C Blázquez Romero"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramon Y Cajal, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "T Carrasco Corral"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "S Corrales Krohnert"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "I Heras Hidalgo"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "H Gavilán Gigosos"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "O Gómez Manrique"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "P Álvarez Pérez"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "A Baldominos Cordón"
    },
    {
      "affiliations": [
        "Hospital Universitario De Guadalajara, Hospital Pharmacy, Guadalajara, Spain"
      ],
      "name": "AM Horta Hernández"
    }
  ],
  "title": "4CPS-306 Semaglutide in obese haemodialysis patients with chronic kidney disease: a case series",
  "uid": "d2efb877-83c0-5b14-95b4-bbe89fd99b4a"
}